The University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA
Hyaluronan (HA)-binding proteins, such as the cell-surface CD44 proteoglycan family and the Receptor for Hyaluronoan-Mediated Motility (RHAMM/CD168), have been implicated in diverse functions, including cell migration, inflammation, lymphocyte activation, and tumor progression. Therefore, they represent attractive therapeutic targets for a number of diseases. Potential differences between species used in the preclinical development of therapeutics against these targets may present challenges. This session will highlight some of the challenges encountered when using animal models for therapeutics designed for use in humans. Optimizing the predictive capabilities of these animal model studies to support the development of human therapeutics and imaging products will be emphasized.